Overlapping Effects of miR-21 Inhibition and Drugs for Idiopathic Pulmonary Fibrosis: Rationale for Repurposing Nintedanib as a Novel Treatment for Ischemia/Reperfusion Injury.
J Cardiovasc Pharmacol
; 77(3): 332-333, 2021 03 01.
Article
em En
| MEDLINE
| ID: mdl-33394826
ABSTRACT
ABSTRACT A specific anti-miR-21 has emerged as an effective treatment for ischemia/reperfusion injury in a pig model of myocardial infarction (MI), but the perspectives for clinical translation are limited. Anti-miR-21 blunts profibrotic pathways, whose excessive activation is detrimental in the post-MI setting. Repurposing antifibrotic drugs approved for other indications is a possible strategy. We compared the molecular effects of anti-miR-21 and the 2 drugs approved for idiopathic pulmonary fibrosis (nintedanib and pirfenidone) through a bioinformatic approach. We report that nintedanib and anti-miR-21 share many targets, including the proto-oncogene Rous sarcoma oncogene cellular homolog. Conversely, pirfenidone and anti-miR-21 do not have common mechanisms of action. In summary, the molecular mechanisms activated by nintedanib are partially overlapping with those elicited by anti-miR-21. Nintedanib could be evaluated in animal studies or clinical trials on MI.
Texto completo:
1
Coleções:
01-internacional
Temas:
Geral
Base de dados:
MEDLINE
Assunto principal:
Piridonas
/
Traumatismo por Reperfusão Miocárdica
/
MicroRNAs
/
Inibidores de Proteínas Quinases
/
Fibrose Pulmonar Idiopática
/
Reposicionamento de Medicamentos
/
Infarto do Miocárdio com Supradesnível do Segmento ST
/
Indóis
/
Pulmão
Limite:
Animals
/
Humans
Idioma:
En
Revista:
J Cardiovasc Pharmacol
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Itália